Zobrazeno 1 - 10
of 12
pro vyhledávání: '"David Revelli"'
Publikováno v:
Frontiers in Microbiology, Vol 14 (2023)
The COVID-19 pandemic, caused by the SARS-CoV-2 virus, has resulted in over 6.7 million deaths worldwide. COVID-19 vaccines administered parenterally via intramuscular or subcutaneous (SC) routes have reduced the severity of respiratory infections, h
Externí odkaz:
https://doaj.org/article/d520156ac4e6403fba97b6d9d93e9e40
Autor:
Aruni Jha, Melanie Doyle-Eisele, David Revelli, Trevor Carnelley, Douglas Barker, Shantha Kodihalli
Publikováno v:
Viruses, Vol 15, Iss 1, p 123 (2022)
Despite ongoing vaccination efforts to prevent SARS-CoV-2 infections, treatment tools are still necessary to address the ongoing COVID-19 pandemic. We report here that COVID-HIGIV, a human immunoglobulin product for treatment of COVID-19, provided a
Externí odkaz:
https://doaj.org/article/af78d50e8e77451e89da422f7f84f586
Autor:
Brad W. Hoff, Zane W. Cohick, Burt S. Tilley, John W. Luginsland, David Revelli, Jason Cox, Hammad Irshad, Amanda Snider, Ariel Arndt, Bennett L. Ibey, Daniel A. Enderich, Robert J. Thomas, Jeremy W. McConaha, Matthew A. Franzi, William P. Roach, Donald A. Shiffler
Publikováno v:
IEEE transactions on bio-medical engineering.
The purpose of the present study is to investigate the inactivation of bioaerosols containing Bovine Coronavirus, BCov, under repetitively pulsed radio frequency (RF) electromagnetic exposure.These experiments were performed in a waveguide containing
Autor:
Charles Jakielaszek, Mohammad Hossain, Lian Qian, Cindy Fishman, Katherine Widdowson, Jamese J. Hilliard, Frank Mannino, Aparna Raychaudhuri, Elisabeth Carniel, Samandra Demons, Henry S. Heine, Jeremy Hershfield, Riccardo Russo, William M. Mega, David Revelli, Karen O’Dwyer
Publikováno v:
Science Translational Medicine. 14
Gepotidacin is a first-in-class triazaacenaphthylene antibacterial agent that selectively inhibits bacterial DNA gyrase and topoisomerase IV through a unique binding mode and has the potential to treat a number of bacterial diseases. Development of t
Autor:
Mathewos Tessema, Steven A. Belinsky, Wendy W Dye, Wenshu Chen, David Revelli, Devon B Dubose, Christin M. Yingling, Michael Burke, Philip J. Kuehl
Publikováno v:
Drug Delivery, Vol 28, Iss 1, Pp 767-775 (2021)
Drug Delivery
article-version (VoR) Version of Record
Drug Delivery
article-version (VoR) Version of Record
Topotecan is potent anti-cancer drug approved for various malignancies but hematopoietic toxicities undermine its wider application and use of its most effective dose. This study aims to improve these limitations through inhalation-delivery. The phar
Autor:
Christian John Ventura, Philip J. Kuehl, Xammy Nguyenla, Marco Antonio Mena, Douglas M. Fox, Robert O. Williams, David Revelli, Chaeho Moon, Steven J Henry, Christopher J. Emig, Dale J. Christensen, Haiyue Xu, Zhengrong Cui, Adela Vitug, Sawittree Sahakijjpijarn
Infections from the SARS-CoV-2 virus have killed over 4.6 million people since it began spreading through human populations in late 2019. In order to develop a therapeutic or prophylactic antibody to help mitigate the effects of the pandemic, a human
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::31b13b5c148fc34a20609e0a9c9af3d0
https://doi.org/10.1101/2021.10.12.464150
https://doi.org/10.1101/2021.10.12.464150
Autor:
David Revelli, Jonathan L. Cape, Lauren Switala, Amanda M. Pluntze, John M. Baumann, Michael Banks, Yue Zhou, Philip J. Kuehl, Kimberly B. Shepard, Julia C. Oddo, Molly S. Adam, David T. Vodak
Publikováno v:
AAPS PharmSciTech
Local delivery of biotherapeutics to the lung holds great promise for treatment of lung diseases, but development of physically stable, biologically active dry powder formulations of large molecules for inhalation has remained a challenge. Here, spra
Autor:
Brad W. Hoff, Michael Geiler, John W. Luginsland, David Revelli, Jeremy W. McConaha, Hugh Pohle, Anton L. Geiler, P. David Lepell, James A. Schrock, Jason Cox, Casey Ottesen, Matthew A. Franzi, Hammad Irshad, Daniel Enderich, Zane Cohick, Thomas B. Montoya
Publikováno v:
The Review of scientific instruments. 92(6)
A system capable of exposing a flowing aerosol stream to short duration (2–4 ns), high-power RF waveforms is described. The system utilizes a C-band gyromagnetic nonlinear transmission line source having peak power outputs ranging as high as 80 kW
Autor:
Andreas Schmitt-Sody, Naomi C. Lewis, Jeremy W. McConaha, Hammad Irshad, Michael T. Lanagan, David Revelli, Jason Cox, John W. Luginsland, Brad W. Hoff, Anthony E. Baros, Matthew A. Franzi, Hugh Pohle, Daniel Enderich, Zane Cohick, Steven Edward Perini, S. C. Schaub
Publikováno v:
The Review of scientific instruments. 92(1)
A set of three apparatus enabling RF exposure of aerosolized pathogens at four chosen frequencies (2.8 GHz, 4.0 GHz, 5.6 GHz, and 7.5 GHz) has been designed, simulated, fabricated, and tested. Each apparatus was intended to operate at high power with
Autor:
Larry M Mallis, David Revelli, Steven A. Belinsky, Carmen S. Tellez, David T. Vodak, Thomas H. March, Michael Burke, Aaron M. Badenoch, Marcie J. Grimes, Philip J. Kuehl, Maria A. Picchi, Wendy W Dye, Devon B Dubose, Tyler Sniegowski, Mathewos Tessema
Publikováno v:
British Journal of Cancer
Background Epigenetic therapy through demethylation of 5-methylcytosine has been largely ineffective in treating lung cancer, most likely due to poor tissue distribution with oral or subcutaneous delivery of drugs such as 5-azacytidine (5AZA). An inh